Issue Date: March 27, 2017
Bristol-Myers signs deal with CytomX
Bristol-Myers Squibb and CytomX Therapeutics are expanding a drug discovery collaboration that dates back to 2014. To four ongoing projects the partners will add up to six cancer and two other drug targets using CytomX’s Probody technology. Bristol-Myers will pay $200 million up front, along with research funding and as much as $448 million in potential milestones for each new target. Probody therapeutics are designed to be activated by proteases in the tumor microenvironment.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society